CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Marchand, L.
Right arrow Articles by Cooney, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Marchand, L.
Right arrow Articles by Cooney, R. V.

Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 6 449-455, Copyright © 1996 by American Association for Cancer Research


ARTICLES

Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?

L Le Marchand, L Sivaraman, AA Franke, LJ Custer, LR Wilkens, AF Lau and RV Cooney
Cancer Research Center of Hawaii, University of Hawaii, Honolulu 96813, USA.

To determine whether NAT2 genotyping could be used interchangeably with caffeine phenotyping in assessing N-acetyltransferase activity in epidemiological studies, sources of interindividual variability in N-acetyltransferase activity were assessed among 90 subjects of various ethnic backgrounds in Hawaii. Forty-three subjects were patients with in situ colorectal cancer treated by polypectomy, and 47 were healthy population controls. Subjects were administered a lifestyle questionnaire and were evaluated for N-acetyltransferase activity by caffeine phenotyping. NAT2 genotype was also assessed by PCR amplification of peripheral leukocyte DNA for the M1, M2, and M3 variant alleles. Fifty-four % of the overall variation in acetylation activity was explained by the three genotype categories (homozygous variant, heterozygous, and homozygous wild-type). This proportion was reduced to 42% when genotype was modeled using only two categories ("slow" being homozygous variant; "rapid" being all others). Use of gout medications (probenecid or allopurinol), consumption of heavily browned fish, and P450IA2 activity (also measured by caffeine phenotyping), together explained another 11% of the variance. No association was found between acetylation activity and sex; race; age; education; smoking; physical activity; weight; consumption of coffee, alcohol, red meat, processed meat, and cruciferous vegetables; or use of menopausal estrogens, after taking genotype into account. Results were similar for colorectal cancer patients and controls. Considerable variation in acetylation activity was observed within the homozygous wild-type group. This study suggests that the use of genotyping, instead of phenotyping, to assess the association of acetylation with cancer risk is unlikely to introduce major misclassification or bias, especially when the three genotype categories are modeled and the sample size is large. However, when the rapid acetylation phenotype is the at-risk group (e.g., when studying colon career), phenotyping appears judicious given the variability in acetylation activity within this group.


This article has been cited by other articles:


Home page
CarcinogenesisHome page
Y. Zang, M. A. Doll, S. Zhao, J. C. States, and D. W. Hein
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
Carcinogenesis, August 1, 2007; 28(8): 1665 - 1671.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. J. Straka, R. T. Burkhardt, N. P. Lang, K. Z. Hadsall, and M. Y. Tsai
Discordance Between N-acetyltransferase 2 Phenotype and Genotype in a Population of Hmong Subjects.
J. Clin. Pharmacol., July 1, 2006; 46(7): 802 - 811.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Le Marchand, J. H. Hankin, L. R. Wilkens, L. M. Pierce, A. Franke, L. N. Kolonel, A. Seifried, L. J. Custer, W. Chang, A. Lum-Jones, et al.
Combined Effects of Well-done Red Meat, Smoking, and Rapid N-Acetyltransferase 2 and CYP1A2 Phenotypes in Increasing Colorectal Cancer Risk
Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1259 - 1266.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. W. Lampe, I. B. King, S. Li, M. T. Grate, K. V. Barale, C. Chen, Z. Feng, and J. D. Potter
Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets
Carcinogenesis, June 1, 2000; 21(6): 1157 - 1162.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
L. L. Marchand
Combined Influence of Genetic and Dietary Factors on Colorectal Cancer Incidence in Japanese Americans
J Natl Cancer Inst Monographs, December 1, 1999; 1999(26): 101 - 105.
[Abstract] [Full Text]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Gross, T. Kruisselbrink, K. Anderson, N. Lang, P. McGovern, R. Delongchamp, and F. Kadlubar
Distribution and Concordance of N-Acetyltransferase Genotype and Phenotype in an American Population
Cancer Epidemiol. Biomarkers Prev., August 1, 1999; 8(8): 683 - 692.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.